NCT02260505 - Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

December 24, 2014

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Gastrointestinal Stromal TumorsResected Gastrointestinal Stromal TumorsNon-metastaticHigh Risk of RecurrenceKIT Gene Mutation

Interventions

DRUG

Imatinib maintenance

Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water

Trial Locations (17)

13273

Institut Paoli-Calmettes, Marseille

13386

Centre Hospitalier Universitaire La Timone, Marseille

21079

Centre Georges François Leclerc, Dijon

25030

CHRU de Besançon - Hôpital Minjoz, Besançon

33076

Institut Bergonié, Bordeaux

34298

Centre Régional de Lutte contre le Cancer de Montpellier, Montpellier

35042

Centre Eugène Marquis, Rennes

42270

Institut de cancérologie LUCIEN NEUWIRTH, Saint-priest-en-jarez

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

51092

Centre Hospitalier universitaire Robert Debré, Reims

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

67098

CHRU Strasbourg - Hôpital Hautepierre, Strasbourg

69008

Centre Léon Bérard, Lyon

75571

AP-HP Hôpital Saint-Antoine, Paris

75908

AP-HP Hôpital Européen Georges Pompidou, Paris

94805

Institut de Cancérologie Gustave Roussy, Villejuif

All Listed Sponsors

lead

Centre Leon Berard

OTHER